公开(公告)号：EP2865669A1

公开(公告)日：2015-04-29

申请号：EP13809037.8

申请日：2013-06-26

申请人： Samjin Pharmaceutical Co., Ltd. ,  Astech. Co., Ltd.

发明人： CHO, Eui-Hwan ,  CHOI, Sung Ju ,  LEE, Sung Woo ,  SHIN, Hee Jong ,  KWON, Ho Seok ,  LEE, Jae Woong ,  JOO, Jeong Ho ,  KIM, Hyun Tae ,  SONG, Woo Heon ,  YOON, Jong Bae ,  PARK, Ki Seok ,  PARK, Ho Joon ,  NAM, Ho Tae

IPC分类号： C07D215/227 ,  C07D413/12 ,  A61K31/4704 ,  A61P1/04

CPC分类号： C07D417/12 ,  A61K31/4704 ,  C07D215/227 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

摘要： Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.

摘要翻译： 公开了一种新型瑞巴派特前药，其制备方法及其用途。 而且，提供了包含作为活性成分的新型瑞巴派特前药的药物组合物。 与瑞巴派特本身相比，瑞巴派特前药的吸收速率增加了25倍，并且可用于预防或治疗胃溃疡，急性胃炎，慢性胃炎，干眼症，癌症，骨关节炎，类风湿性关节炎或肥胖症。

公开(公告)号：EP3412670A1

公开(公告)日：2018-12-12

申请号：EP17747634.8

申请日：2017-01-11

申请人： Samjin Pharmaceutical Co., Ltd. ,  Incheon University Industry Academic Cooperation Foundation ,  BAMICHEM CO., LTD

发明人： CHO, Eui Hwan ,  SHIN, Hee Jong ,  KI, Min Hyo ,  KWON, Ho Seok ,  LEE, Jae Woong ,  JOO, Jeong Ho ,  LEE, Keun Kuk ,  KIM, Jong Min ,  PARK, Yong Bin ,  KANG, Sung Hyun ,  CHO, Hyoung Min ,  KIM, Hyun Tae ,  AHN, Soon Kil ,  HONG, Sung Pyo ,  KIM, Sung Hye

IPC分类号： C07D473/00 ,  C07D487/04 ,  C07D401/04 ,  C07D401/14 ,  A61K31/52 ,  A61K31/519

CPC分类号： A61K31/519 ,  A61K31/52 ,  C07D401/04 ,  C07D401/14 ,  C07D473/00 ,  C07D487/04

摘要： The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.